New cancer treatment and survival: prostate cancer
Castration therapy has been the standard treatment for patients with metastatic prostate cancer for decades. In 2004, the first data showing efficacy of adding docetaxel to patients in the castration refractory phase were published. Over the past decade, additional data have emerged showing efficacy of several other drugs (Abiraterone, Enzalutamide, Cabacitaxel and Radium-223) in the castration-refractory phase. From 2015, data showed gains from adding docetaxel in the hormone-sensitive phase.
The treatment of prostate cancer has changed over the past two decades. Although the new treatments are well documented in studies, little is known about how they are implemented in the treatment in a general population. Nor do we have an overview of the use of these new and often expensive drugs in the Norwegian prostate cancer population.
In this population-based study, we want to describe who has received the new drugs and also look at which patients have not received the treatment. We will also look at survival in the different groups.
In analysing our data, we will focus on:
- Describe patients who have received new drugs, both patients who have metastatic disease at the time of diagnosis and patients who develop metastases. We will describe disease characteristics and socioeconomic. We will also look at what characterises those who have received new drugs vs. those who have not.
- Overall and cancer-specific survival for both primary and secondary metastatic prostate cancer patients before and after the introduction of new treatment regimens
- Prevalence of recurrence after curative treatment and need for systemic treatment in recurrence patients.
This study is based on all patients diagnosed with prostate cancer between 2004 and 2021. We have linked the Cancer Registry data with data from the Norwegian Patient Registry, KUHR, the Norwegian Prescription Database, the Cause of Death Registry and the National Registry/Statistics Norway.
Significance of this study
The purpose of this study is to map the use of new drugs for prostate cancer patients. We want to look at who has received the drugs, when they were introduced to the population and what benefit they have. This knowledge will be useful for both clinicians and patients.
Anne Holck Storås, doctor and specialist in oncology. She is employed at the Department of Urology, Department of Cancer Treatment at Oslo University Hospital and works at the Cancer Registry of Norway as a post-doc.
She did her PhD at the Institute of Clinical Medicine at the University of Oslo with the title Adverse effects after curative treatment for prostate cancer; an international perspective.
Storås AH, Tusuruda K, Haug ES, Fosså SD, Andreassen BK. Recurrence after prostatectomy in Norwegian prostate cancer patients diagnosed in 2008-2018. Autumn Surgical Meeting, Urology 5, 28.10.2022, Oslo, Norway; Oral presentation
Storås AH, Andreassen BK, Fosså SD. Characterization of long-term survivors of primary metastatic prostate cancer patients in Norway. Acta Oncol 2022 May; 61(5): 615-618. doi: 10.1080/0284186X.2022.2051204. PMID: 35300560
Storås AH, Fosså SD, Ursin G, Andreassen BK. Survival trends for patients with primary metastatic prostate cancer before and after the introduction of new antitumor drugs. Prostate Cancer Prostatic Dis 2021 Sep 7; Epub ahead of print. doi: 10.1038/s41391-021-00445-x. PMID: 34493838
PUBMED | Storås AH